STOKE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.48 USD | -4.41% |
|
-4.49% | +118.25% |
| May. 07 | Canaccord Genuity Adjusts Price Target on Stoke Therapeutics to $20 From $21, Maintains Buy Rating | MT |
| May. 06 | Earnings Flash (STOK) STOKE THERAPEUTICS Reports Q1 Revenue $4.2M | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 926.9 | 2,244 | 882.6 | 363.9 | 234.9 | 598.3 | - | - |
| Enterprise Value (EV) 1 | 704.4 | 1,957 | 737.7 | 250.4 | 234.9 | 377.4 | 477 | 440.6 |
| P/E ratio | -15.7 x | -39.7 x | -10.3 x | -3.55 x | -2.21 x | -5.04 x | -4.41 x | -4.72 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | 29.3 x | 26.8 x | 43.6 x | 36.7 x | 22.8 x |
| EV / Revenue | - | - | - | 20.2 x | 26.8 x | 27.5 x | 29.2 x | 16.8 x |
| EV / EBITDA | -20 x | -37.5 x | -8.67 x | -2.44 x | -2.09 x | -3.16 x | -3.11 x | -2.67 x |
| EV / FCF | -21.5 x | -45.2 x | -10.8 x | -6.99 x | - | -3.34 x | -3.99 x | -3.5 x |
| FCF Yield | -4.64% | -2.21% | -9.23% | -14.3% | - | -29.9% | -25.1% | -28.6% |
| Price to Book | 2.27 x | 7.92 x | 4.05 x | 1.94 x | - | 3.13 x | 6.05 x | 4.8 x |
| Nbr of stocks (in thousands) | 32,730 | 36,236 | 36,791 | 39,431 | 44,654 | 52,120 | - | - |
| Reference price 2 | 28.32 | 61.93 | 23.99 | 9.230 | 5.260 | 11.48 | 11.48 | 11.48 |
| Announcement Date | 3/23/20 | 3/9/21 | 3/10/22 | 3/6/23 | 3/25/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | 12.4 | 8.78 | 13.74 | 16.32 | 26.19 |
| EBITDA 1 | -35.23 | -52.16 | -85.09 | -102.8 | -112.3 | -119.6 | -153.4 | -164.8 |
| EBIT 1 | -35.68 | -53.04 | -86.06 | -104.4 | -114.8 | -124.8 | -151.6 | -166.8 |
| Operating Margin | - | - | - | -841.24% | -1,307.21% | -908.56% | -929.25% | -636.83% |
| Earnings before Tax (EBT) 1 | -32.32 | -52.24 | -85.8 | -101.1 | -104.7 | -115.7 | -143.3 | -150.4 |
| Net income 1 | -32.32 | -52.24 | -85.8 | -101.1 | -104.7 | -114.8 | -143.6 | -153.5 |
| Net margin | - | - | - | -814.73% | -1,192.47% | -835.38% | -879.74% | -586.25% |
| EPS 2 | -1.800 | -1.560 | -2.340 | -2.600 | -2.380 | -2.277 | -2.601 | -2.430 |
| Free Cash Flow 1 | -32.69 | -43.27 | -68.11 | -35.83 | - | -113 | -119.6 | -126 |
| FCF margin | - | - | - | -288.82% | - | -822.36% | -732.79% | -481.23% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/23/20 | 3/9/21 | 3/10/22 | 3/6/23 | 3/25/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 3 | 3.231 | 2.905 | 3.269 | 5.152 | -2.481 | 3.308 | 2.802 | 4.216 | 3.256 | 3.311 | 3.233 |
| EBITDA 1 | -24.29 | -24.55 | -24.94 | -26.76 | -26.57 | -24.09 | -32.65 | - | -28.96 | - | -29.3 | -30.8 | -31.8 |
| EBIT 1 | -24.53 | -24.8 | -25.24 | -27.15 | -27.18 | -24.69 | -33.26 | -27.23 | -29.59 | -28.37 | -30.99 | -32.09 | -32.81 |
| Operating Margin | - | -826.5% | -781.12% | -934.53% | -831.29% | -479.23% | 1,340.67% | -823.28% | -1,055.89% | -672.96% | -952% | -969.18% | -1,014.67% |
| Earnings before Tax (EBT) 1 | -24.45 | -24.65 | -24.65 | -26.11 | -25.66 | -22.54 | -30.65 | -24.54 | -26.96 | -26.37 | -28.68 | -29.68 | -30.53 |
| Net income 1 | -24.45 | -24.65 | -24.65 | -26.11 | -25.66 | -22.54 | -30.65 | -24.54 | -26.96 | -26.37 | -27.66 | -29.08 | -30.4 |
| Net margin | - | -821.63% | -762.98% | -898.83% | -784.8% | -437.6% | 1,235.55% | -741.9% | -962.1% | -625.57% | -849.58% | -878.32% | -940.15% |
| EPS 2 | -0.6600 | -0.6600 | -0.6300 | -0.6600 | -0.6500 | -0.5300 | -0.6900 | -0.5500 | -0.6000 | -0.5700 | -0.5493 | -0.5704 | -0.5921 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/10/22 | 5/10/22 | 8/8/22 | 11/14/22 | 3/6/23 | 5/4/23 | 8/7/23 | 11/7/23 | 3/25/24 | 5/6/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 222 | 287 | 145 | 114 | - | 221 | 121 | 158 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -32.7 | -43.3 | -68.1 | -35.8 | - | -113 | -120 | -126 |
| ROE (net income / shareholders' equity) | -19.6% | -20.5% | -34.1% | -50.2% | - | -63.6% | -88.9% | -119% |
| ROA (Net income/ Total Assets) | -19.2% | -19.8% | -32% | -40.8% | - | -42.6% | -61.7% | -87.2% |
| Assets 1 | 168.1 | 263.3 | 268.4 | 247.5 | - | 269.3 | 232.7 | 176.2 |
| Book Value Per Share 2 | 12.50 | 7.820 | 5.930 | 4.750 | - | 3.670 | 1.900 | 2.390 |
| Cash Flow per Share 2 | - | -1.260 | -1.820 | -0.8200 | - | -1.870 | -1.690 | -1.600 |
| Capex 1 | 1.64 | 1.05 | 1.2 | 3.96 | - | 2.87 | 2.44 | 4.6 |
| Capex / Sales | - | - | - | 31.94% | - | 20.92% | 14.98% | 17.57% |
| Announcement Date | 3/23/20 | 3/9/21 | 3/10/22 | 3/6/23 | 3/25/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
11.48
USD
Average target price
22.14
USD
Spread / Average Target
+92.88%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +118.25% | 598M | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +47.41% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- STOK Stock
- Financials Stoke Therapeutics, Inc.